New evidence compares micro-ultrasound and MRI fusion biopsy for detecting clinically significant prostate cancer. Find out ...

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

In patients with elevated PSA, the urinary MPS2 test had high accuracy for ruling out high-grade prostate cancer requiring biopsy. The urinary 18-gene MyProstateScore 2.0 (MPS2) test can detect ...

An artificial intelligence system slightly outperformed radiologists using PI-RADS at detecting clinically significant prostate cancer. A trained artificial intelligence (AI) system discriminated ...

Using PROTECT trial data, investigators assessed the possible benefit of early treatment vs active monitoring for cribriform-positive prostate cancer.

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

Among more than 3000 men from low-income communities who were screened for various health issues at mobile clinics, one had stage IV and none had metastatic prostate cancer. These were among the ...

In a cohort of US veterans with prostate cancer who were on active surveillance, negative multiparametric MRI had a 75% negative predictive value for ruling out disease of grade group 2 or higher at ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...